ArticleJournal of medical screening2022
COVID-19 disruption to cervical cancer screening in England.
Article in Journal of medical screening, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Impact of the COVID-19 Pandemic on Breast and Cervical Cancer Screening: A Systematic Review.In vivo (Athens, Greece)Pooled it
- Evolving attitudes towards cancer screening: a 2024 update of UK population views.British journal of cancer · 2026Article
- Barriers and facilitators to using self-sampled tests for the human papillomavirus (HPV): a mixed-methods study to inform a horizon scan.International journal of technology assessment in health care · 2026Article
- Understanding knowledge, beliefs, values and barriers towards cervical cancer screening and self-sampling amongst migrant Muslim women in Southwest London: an in-depth qualitative interview study.BMJ public health · 2026Article
- COVID-19 vaccination rates as a proxy for health system resilience: implications of development disparities for cervical cancer control during the pandemic.Frontiers in medicine · 2026Article
- HPV vaccination coverage rate in women undergoing conization for cervical intraepithelial neoplasia in Spain: The COVAR study.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2025Article
- HPValidate-human papillomavirus testing with DNA and mRNA assays on self-collected samples in cervical screening: comparison of test characteristics on three self-sampling devices.British journal of cancer · 2025Article
- Advancing Cervical Cancer Prevention Equity: Innovations in Self-Sampling and Digital Health Technologies Across Healthcare Settings.Diagnostics (Basel, Switzerland) · 2025Review
- Recommendations for a Communication Strategy to Support Informed Decision-Making About Self or Clinician Sampling for Cervical Screening in the UK: Qualitative Study.Health expectations : an international journal of public participation in health care and health policy · 2025Article
- Functional Limitations and Use of General Health Examination and Cancer Screening Among People with Disabilities Who Need Support from Others: Secondary Data Analysis of the 2022 Comprehensive Survey of Living Conditions in Japan.International journal of environmental research and public health · 2025Article
- Addressing COVID-19 Screening Delays: The Impact of HPV Self-Sampling on Non-Attenders in a Cervical Cancer Screening Program.Cancers · 2024Article
- Opportunities and challenges encountered in managing cervical cancer during the coronavirus disease 2019 pandemic.Infectious agents and cancer · 2024Review
- Cervical cancer in Thailand: 2023 update.Obstetrics & gynecology science · 2024Article
- Factors associated with cervical screening coverage: a longitudinal analysis of English general practices from 2013 to 2022.Journal of public health (Oxford, England) · 2024Article
- Exploring the Impact of COVID-19 on Cervical Cancer Screening Services: A Qualitative Study of Healthcare Providers' and Women's Perspectives and Experiences.Health services insights · 2024Article
- Impact of the COVID-19 pandemic on cervical cancer screening participation, abnormal cytology prevalence and screening interval in Catalonia.Frontiers in oncology · 2024Article
- Article
- Article
- HPV and Cervical Cancer: A Review of Epidemiology and Screening Uptake in the UK.Pathogens (Basel, Switzerland) · 2023Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
introductionIn England, routine invitations for cervical screening were reduced between April 2020 and June 2020 due to the COVID-19 pandemic. We quantify the impact of COVID-19 disruptions on attendance and excess diagnoses of cervical cancer (CC).
methodsUsing Public Health England CC screening data on laboratory samples received in 2018 as a baseline we quantify the reduction in screening attendances due to the COVID-19 pandemic between April 2020 and March 2021 for women aged 25-64. We model the impact on excess CC diagnoses assuming once invitations resume 87.5% of women attend within 12 months and 12.5% delay screening for 3 or 5 years (depending on age).
resultsThe number of samples received at laboratories was 91% lower than expected during April, 85% during May and 43% during June 2020 compared to the same period in 2018. Although on average laboratories received 12.6% more samples between August 2020 and April 2021 than over the same months in 2018, by April 2021 there was a short fall of 200,949 samples (6.4% fewer than in 2018). An excess of 41 CC (4.0 per 100,000 women with a maximum screening delay of 12 months) are predicted to occur among the estimated 1,024,794 women attending this screening round with a delay. An excess of 60 CC (41.0 per 100,000 women) are predicted to occur among the estimated 146,391 women who do not attend this screening round.
conclusionPrompt restoration of cervical screening services limited the impact on excess CC diagnoses. However, in 2020 a 6.4% shortfall of screening samples was observed. Every effort should be made to reassure these women that services are open and safe to attend.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.